Showing results (1421-1430 of 4,565) with videos related to

Sort By:
Pageof 457
Advances in Therapy|May 20, 2021
Overexpression of NOP58 as a Prognostic Marker in Hepatocellular Carcinoma: A TCGA Data-Based AnalysisJinpo Wang, Rongfeng Huang, Yuehong Huang, et al.
Advances in Therapy|May 22, 2021
Cost-Effectiveness of Tisagenlecleucel in Paediatric Acute Lymphoblastic Leukaemia (pALL) and Adult Diffuse Large B-Cell Lymphoma (DLBCL) in SwitzerlandMaziar Moradi-Lakeh, Mohsen Yaghoubi, Patrick Seitz, et al.
Advances in Therapy|May 21, 2021
Cost-Effectiveness of Atezolizumab Plus Chemotherapy as First-Line Therapy for Metastatic Urothelial CancerShuxia Qin, Lidan Yi, Sini Li, et al.
Advances in Therapy|May 25, 2021
Comparative Effectiveness and Safety of Rivaroxaban and Warfarin Among Nonvalvular Atrial Fibrillation (NVAF) Patients with Obesity and Polypharmacy in the United States (US)Jeffrey S Berger, François Laliberté, Akshay Kharat, et al.
Advances in Therapy|May 5, 2021
Evaluation of the Octreotide Acetate Pen Injector and its Instructions for Use in a Formative Human Factors StudyAnthony Andre, Nicholas Squittieri, Satyashodhan B Patil
Advances in Therapy|April 28, 2021
Quantitative Evaluation of Aerosol Generation from Non-contact Tonometry and its Correlation with Tear Film CharacteristicsWeiting Hao, Jianhui Wu, Xinheng Zhao, et al.
Advances in Therapy|June 24, 2015
Tiotropium and Salmeterol in COPD Patients at Risk of Exacerbations: A Post Hoc Analysis from POET-COPD(®)Claus F Vogelmeier, Guus M Asijee, Katrin Kupas, et al.
Advances in Therapy|May 27, 2020
Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Mini-Tabs Plus Ribavirin for Children Aged 3-11 Years with Hepatitis C Genotype 1aPhilip Rosenthal, Michael R Narkewicz, Betty B Yao, et al.
Advances in Therapy|May 22, 2020
Development and Validation of a Nomogram-Based Prognostic Evaluation Model for Sarcomatoid Hepatocellular CarcinomaDazhuang Ge, Zhiwen Luo, Rui Mao, et al.
Advances in Therapy|May 22, 2020
Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying TherapyJames Bowen, Rina Mehta, Corey Pelletier, et al.
Pageof 457